Actimed Therapeutics

Actimed Therapeutics is a clinical-stage biopharmaceutical company dedicated to innovating treatments for muscle wasting disorders, particularly cancer cachexia, a severe syndrome associated with various chronic illnesses. Founded in 2017 by Stefan Anker and Andrew Coats in Ascot, Windsor and Maidenhead, the company develops anabolic and catabolic transforming agents aimed at addressing this often fatal condition. By focusing on the management of cancer-related cachexia, Actimed Therapeutics seeks to improve care for a vulnerable patient population that has been historically underserved in this area.